U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30N4O2S2
Molecular Weight 446.629
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THIOPROPERAZINE

SMILES

CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(C)CC4)C=C1

InChI

InChIKey=VZYCZNZBPPHOFY-UHFFFAOYSA-N
InChI=1S/C22H30N4O2S2/c1-23(2)30(27,28)18-9-10-22-20(17-18)26(19-7-4-5-8-21(19)29-22)12-6-11-25-15-13-24(3)14-16-25/h4-5,7-10,17H,6,11-16H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C22H30N4O2S2
Molecular Weight 446.629
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/thioproperazine.html | https://www.ncbi.nlm.nih.gov/pubmed/13661859 | https://www.ncbi.nlm.nih.gov/pubmed/16777448 | https://www.ncbi.nlm.nih.gov/pubmed/1354163 | https://www.ncbi.nlm.nih.gov/pubmed/4379824 | http://eci2012.net/wp-content/uploads/2015/03/Majeptil-PM-En-160702.01-20Feb2015.pdf

Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually without antiserotonin and hypotensive action and has no antihistaminic property. It is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. Overdosage may result in severe extrapyramidal symptoms with dysphagia, marked sialorrhea, persistent and rapidly increasing hyperthermia, pulmonary syndrome, state of shock with pallor and profuse sweating, which may be followed by collapse and coma.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.45 nM [Ki]
1.2 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Majeptil

Approved Use

INDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Primary
Majeptil

Approved Use

INDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Primary
Majeptil

Approved Use

INDICATIONS. All types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
PubMed

PubMed

TitleDatePubMed
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy.
1967
Correlative neuroanatomical and neuropharmacological study of tremor and catatonia in the monkey.
1971 May
Analysis of phenothiazines in human body fluids using disk solid-phase extraction and liquid chromatography.
2005 Nov-Dec
Simple and simultaneous determination for 12 phenothiazines in human serum by reversed-phase high-performance liquid chromatography.
2007 Jul 1
Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settings.
2008 Feb
Research on antipsychotics in India.
2010 Jan
An overview of Indian research in schizophrenia.
2010 Jan
Methotrimeprazine-induced corneal deposits and cataract revealed by urine drug profiling test.
2010 Nov
Patents

Patents

Sample Use Guides

Adults: It is recommended to start treatment at a low dosage of about 5 mg per day in a single dose or in divided doses. This initial dosage is gradually increased by the same amount every 2 to 3 days until the usual effective dosage of 30 to 40 mg per day is reached. In some cases higher dosages of 90 mg or more per day, are necessary to control the psychotic manifestations. Children: In children over 10 years: Start treatment with a daily dosage of 1 to 3 mg following the method of treatment described for adults.
Route of Administration: Oral
In Vitro Use Guide
The effects of drugs on biochemical parameters of red blood cells were assessed using 100 ml human blood, which was obtained from a volunteer and diluted with 15 ml of 16 mM citric acid, 113 mM sodium citrate, 21 mM monosodium phosphate, 140 mM glucose, and 2 mM adenine at pH 7.4. Thioproperazine samples were added to 10-ml aliquots of blood to give a final concentration of 1 mM, and the blood was stored at 4 C. The pH of the blood was routinely measured, and 2-ml samples were taken. The cells were pelleted by centrifugation at 3000gma x for 5 rain, and the supernatants were removed. Two volumes of 15% (w/v) trichloroacetic acid were added to 1 vol of packed cells and, after standing on ice for 10 rain, the denatured protein was removed by centrifugation. The acid-soluble fraction was extracted four times with copious amounts of water-saturated diethyl ether to remove the trichloracetic acid and was assayed for 2,3-diphosphoglyceric acid levels using spectrophotometric methods
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:42:37 GMT 2023
Edited
by admin
on Fri Dec 15 15:42:37 GMT 2023
Record UNII
YJ050AQ56X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THIOPROPERAZINE
INN   MI   WHO-DD  
INN  
Official Name English
Thioproperazine [WHO-DD]
Common Name English
thioproperazine [INN]
Common Name English
THIOPROPERAZINE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QN05AB08
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
NCI_THESAURUS C29710
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
WHO-ATC N05AB08
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
Code System Code Type Description
EVMPD
SUB10983MIG
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
CHEBI
59120
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
DRUG CENTRAL
2635
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
SMS_ID
100000082127
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
RXCUI
10498
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY RxNorm
INN
911
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
PUBCHEM
9429
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
MERCK INDEX
m10780
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY Merck Index
CAS
316-81-4
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
DRUG BANK
DB01622
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
FDA UNII
YJ050AQ56X
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
EPA CompTox
DTXSID1023655
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
MESH
C084825
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-262-4
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
NCI_THESAURUS
C73292
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
WIKIPEDIA
THIOPROPERAZINE
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
ChEMBL
CHEMBL609109
Created by admin on Fri Dec 15 15:42:37 GMT 2023 , Edited by admin on Fri Dec 15 15:42:37 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY